Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)
Status:
Completed
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase I study is to evaluate the safety and tolerability of ALLN-346 in
in normal healthy volunteers, in an ascending dose design.
ALLN-346 is an (oral) enzyme that specifically degrades urate in the intestinal tract.